Skip to main content

Targeting cancer evolution in the clinic

Guest Editors: Razelle Kurzrock and Alberto Bardelli

New Content ItemGenome Medicine is pleased to present a special issue on ‘Targeting cancer evolution in the clinic,’ guest-edited by Dr. Razelle Kurzrock from the University of San Diego and Dr. Alberto Bardelli from the University of Torino. Progress in the understanding of cancer evolution, heterogeneity, and metastasis has accelerated in recent years due in large part to advancements in sequencing technology. The advent of massively parallel sequencing has encouraged extensive tumor mutational profiling efforts, mapping of cancer genomic landscapes, and widespread tracking of genomes longitudinally from cancer development, to metastasis, and eventually to therapeutic response and resistance. Particularly intriguing are attempts to translate these insights into the clinic, where they can be utilized for precision medicine from prevention, risk prediction and early detection, to therapeutic targeting, longitudinal monitoring, and prognosis. The tracking of clonal dynamics to determine driver mutations, monitor potential resistant subpopulations, and gauge response to therapy represents a promising strategy for clinical cancer medicine. 

This special issue aims to capture advances in this growing area, covering the breadth of cancer evolution and clinical cancer therapeutics including clonal evolution and dynamics, tumor heterogeneity and clonal diversity, metastases, precision medicine and therapeutics, longitudinal monitoring, and treatment response and clonal resistance.

This collection of articles has not been sponsored and articles will undergo the journal’s standard peer-review process. The Guest Editors declare that they have no competing interests. Guest Editors serve an advisory role to guide the scope of the special issue and commissioned content; final editorial decisions lie with the Editor.

  1. Lung adenocarcinoma, the most common type of lung cancer, has a high level of morphologic heterogeneity and is composed of tumor cells of multiple histological subtypes. It has been reported that immune cell i...

    Authors: Thinh T. Nguyen, Hyun-Sung Lee, Bryan M. Burt, Jia Wu, Jianjun Zhang, Christopher I. Amos and Chao Cheng

    Citation: Genome Medicine 2022 14:5

    Content type: Research

    Published on:

  2. Endometrial cancer (EC) is a major gynecological cancer with increasing incidence. It comprises four molecular subtypes with differing etiology, prognoses, and responses to chemotherapy. In the future, clinica...

    Authors: Vanessa F. Bonazzi, Olga Kondrashova, Deborah Smith, Katia Nones, Asmerom T. Sengal, Robert Ju, Leisl M. Packer, Lambros T. Koufariotis, Stephen H. Kazakoff, Aimee L. Davidson, Priya Ramarao-Milne, Vanessa Lakis, Felicity Newell, Rebecca Rogers, Claire Davies, James Nicklin…

    Citation: Genome Medicine 2022 14:3

    Content type: Research

    Published on:

  3. While understanding molecular heterogeneity across patients underpins precision oncology, there is increasing appreciation for taking intra-tumor heterogeneity into account. Based on large-scale analysis of ca...

    Authors: Chayaporn Suphavilai, Shumei Chia, Ankur Sharma, Lorna Tu, Rafael Peres Da Silva, Aanchal Mongia, Ramanuj DasGupta and Niranjan Nagarajan

    Citation: Genome Medicine 2021 13:189

    Content type: Method

    Published on:

  4. We present Beyondcell, a computational methodology for identifying tumour cell subpopulations with distinct drug responses in single-cell RNA-seq data and proposing cancer-specific treatments. Our method calcu...

    Authors: Coral Fustero-Torre, María José Jiménez-Santos, Santiago García-Martín, Carlos Carretero-Puche, Luis García-Jimeno, Vadym Ivanchuk, Tomás Di Domenico, Gonzalo Gómez-López and Fátima Al-Shahrour

    Citation: Genome Medicine 2021 13:187

    Content type: Method

    Published on:

  5. Cancer is a somatic evolutionary disease and adenocarcinomas of the stomach and gastroesophageal junction (GC) may serve as a two-dimensional model of cancer expansion, in which tumor subclones are not evenly ...

    Authors: Christoph Röcken, Anu Amallraja, Christine Halske, Luka Opasic, Arne Traulsen, Hans-Michael Behrens, Sandra Krüger, Anne Liu, Jochen Haag, Jan-Hendrik Egberts, Philip Rosenstiel and Tobias Meißner

    Citation: Genome Medicine 2021 13:177

    Content type: Research

    Published on:

  6. Metastatic breast cancer is a deadly disease with a low 5-year survival rate. Tracking metastatic spread in living patients is difficult and thus poorly understood.

    Authors: Xiaomeng Huang, Yi Qiao, Samuel W. Brady, Rachel E. Factor, Erinn Downs-Kelly, Andrew Farrell, Jasmine A. McQuerry, Gajendra Shrestha, David Jenkins, W. Evan Johnson, Adam L. Cohen, Andrea H. Bild and Gabor T. Marth

    Citation: Genome Medicine 2021 13:170

    Content type: Research

    Published on:

  7. Liver cancer is one of the most commonly diagnosed cancers and the fourth leading cause of cancer-related death worldwide. Broad-spectrum kinase inhibitors like sorafenib and lenvatinib provide only modest sur...

    Authors: Yuchen Guo, Jun Wang, Bente Benedict, Chen Yang, Frank van Gemert, Xuhui Ma, Dongmei Gao, Hui Wang, Shu Zhang, Cor Lieftink, Roderick L. Beijersbergen, Hein te Riele, Xiaohang Qiao, Qiang Gao, Chong Sun, Wenxin Qin…

    Citation: Genome Medicine 2021 13:166

    Content type: Research

    Published on:

  8. Tumor mutational burden (TMB) may be a predictive biomarker of immune checkpoint inhibitor (ICI) responsiveness. Genomic landscape heterogeneity is a well-established cancer feature. Molecular characteristics ...

    Authors: Timothy V. Pham, Aaron M. Goodman, Smruthy Sivakumar, Garrett Frampton and Razelle Kurzrock

    Citation: Genome Medicine 2021 13:159

    Content type: Research

    Published on:

  9. Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced ...

    Authors: Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam, Paul T. Fanta, Michael E. Hahn, Pradip De, Casey Williams, Jessica Guido, Benjamin M. Solomon, Rana R. McKay, Amy Krie, Sarah G. Boles, Jeffrey S. Ross, J. Jack Lee…

    Citation: Genome Medicine 2021 13:155

    Content type: Research

    Published on:

  10. Epstein-Barr virus (EBV)-associated gastric carcinomas (EBVaGCs) present unique molecular signatures, but the tumorigenesis of EBVaGCs and the role EBV plays during this process remain poorly understood.

    Authors: Zhang-Hua Chen, Shu-Mei Yan, Xi-Xi Chen, Qi Zhang, Shang-Xin Liu, Yang Liu, Yi-Ling Luo, Chao Zhang, Miao Xu, Yi-Fan Zhao, Li-Yun Huang, Bin-Liu Liu, Tian-Liang Xia, Da-Zhi Xu, Yao Liang, Yong-Ming Chen…

    Citation: Genome Medicine 2021 13:146

    Content type: Research

    Published on:

  11. We developed a sensitive sequencing approach that simultaneously profiles microsatellite instability, chromosomal instability, and subclonal structure in cancer. We assessed diverse repeat motifs across 225 mi...

    Authors: GiWon Shin, Stephanie U. Greer, Erik Hopmans, Susan M. Grimes, HoJoon Lee, Lan Zhao, Laura Miotke, Carlos Suarez, Alison F. Almeda, Sigurdis Haraldsdottir and Hanlee P. Ji

    Citation: Genome Medicine 2021 13:145

    Content type: Method

    Published on:

  12. Gene expression-based subtyping has the potential to form a new paradigm for stratified treatment of colorectal cancer. However, current frameworks are based on the transcriptomic profiles of primary tumors, a...

    Authors: Seyed H. Moosavi, Peter W. Eide, Ina A. Eilertsen, Tuva H. Brunsell, Kaja C. G. Berg, Bård I. Røsok, Kristoffer W. Brudvik, Bjørn A. Bjørnbeth, Marianne G. Guren, Arild Nesbakken, Ragnhild A. Lothe and Anita Sveen

    Citation: Genome Medicine 2021 13:143

    Content type: Research

    Published on:

  13. Colorectal cancer is the 2nd leading cause of cancer-related deaths with few patients benefiting from biomarker-guided therapy. Mutation expression is essential for accurate interpretation of mutations as biom...

    Authors: Anita Sveen, Bjarne Johannessen, Ina A. Eilertsen, Bård I. Røsok, Marie Gulla, Peter W. Eide, Jarle Bruun, Kushtrim Kryeziu, Leonardo A. Meza-Zepeda, Ola Myklebost, Bjørn A. Bjørnbeth, Rolf I. Skotheim, Arild Nesbakken and Ragnhild A. Lothe

    Citation: Genome Medicine 2021 13:142

    Content type: Research

    Published on:

  14. The enrichment of Gram-negative bacteria of oral origin in the esophageal microbiome has been associated with the development of metaplasia. However, to date, no study has comprehensively assessed the relation...

    Authors: Nandan P. Deshpande, Stephen M. Riordan, Claire J. Gorman, Shaun Nielsen, Tonia L. Russell, Carolina Correa-Ospina, Bentotage S. M. Fernando, Shafagh A. Waters, Natalia Castaño-Rodríguez, Si Ming Man, Nicodemus Tedla, Marc R. Wilkins and Nadeem O. Kaakoush

    Citation: Genome Medicine 2021 13:133

    Content type: Research

    Published on:

  15. Tumor response to therapy is affected by both the cell types and the cell states present in the tumor microenvironment. This is true for many cancer treatments, including immune checkpoint inhibitors (ICIs). W...

    Authors: Emily F. Davis-Marcisak, Allison A. Fitzgerald, Michael D. Kessler, Ludmila Danilova, Elizabeth M. Jaffee, Neeha Zaidi, Louis M. Weiner and Elana J. Fertig

    Citation: Genome Medicine 2021 13:129

    Content type: Research

    Published on:

  16. Cancer evolution depends on epigenetic and genetic diversity. Historically, in multiple myeloma (MM), subclonal diversity and tumor evolution have been investigated mostly from a genetic perspective.

    Authors: Jennifer Derrien, Catherine Guérin-Charbonnel, Victor Gaborit, Loïc Campion, Magali Devic, Elise Douillard, Nathalie Roi, Hervé Avet-Loiseau, Olivier Decaux, Thierry Facon, Jan-Philipp Mallm, Roland Eils, Nikhil C. Munshi, Philippe Moreau, Carl Herrmann, Florence Magrangeas…

    Citation: Genome Medicine 2021 13:127

    Content type: Research

    Published on:

  17. The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Her...

    Authors: Deepak Vangala, Swetlana Ladigan, Sven T. Liffers, Soha Noseir, Abdelouahid Maghnouj, Tina-Maria Götze, Berlinda Verdoodt, Susanne Klein-Scory, Laura Godfrey, Martina K. Zowada, Mario Huerta, Daniel L. Edelstein, Jaime Martinez de Villarreal, Miriam Marqués, Jörg Kumbrink, Andreas Jung…

    Citation: Genome Medicine 2021 13:116

    Content type: Research

    Published on:

  18. Malignant pleural mesothelioma (MPM) is a heterogeneous cancer. Better knowledge of molecular and cellular intra-tumor heterogeneity throughout the thoracic cavity is required to develop efficient therapies. T...

    Authors: Clément Meiller, François Montagne, Theo Z. Hirsch, Stefano Caruso, Julien de Wolf, Quentin Bayard, Jean-Baptiste Assié, Léa Meunier, Yuna Blum, Lisa Quetel, Laure Gibault, Ecaterina Pintilie, Cécile Badoual, Sarah Humez, Françoise Galateau-Sallé, Marie-Christine Copin…

    Citation: Genome Medicine 2021 13:113

    Content type: Research

    Published on: